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Cinnamaldehyde (Cin), cinnamic acid (Ca) and cinnamyl alcohol (Cal), major constituents of Cinnamomum cassia,h a v eb e e n
shown to possess antioxidant, anti-inﬂammatory, anticancer and other activities. In this study, our aim was to evaluate the
antiproliferative activity of these compounds in human hepatoma Hep G2 cells and examine the eﬀects of piﬁthrin-alpha (PFTα;
a speciﬁc p53 inhibitor) on their apoptotic signaling transduction mechanism. The antiproliferative activity was measured by
XTT assay. Expression of apoptosis-related proteins was detected by western blotting. Results showed that at a concentration
of 30μM, the order of antiproliferative activity in Hep G2 cells was Cin> Ca> Cal. Cin (IC50 9.76 ± 0.67μM) demonstrated
an antiproliferative potency as good as 5-ﬂuorouracil (an anti-cancer drug; IC50 9.57 ± 0.61μM). Further studies on apoptotic
mechanisms of Cin showed that it downregulated the expression of Bcl-XL, upregulated CD95 (APO-1), p53 and Bax proteins,
as well as cleaving the poly (ADP-ribose) polymerase (PARP) in a time-dependent pattern. PFTα pre-incubation signiﬁcantly
diminishedtheeﬀectofCin-inducedapoptosis.Itmarkedlyupregulatedtheanti-apoptotic(Bcl-XL)expressionanddownregulated
the pro-apoptotic (Bax) expression, as well as eﬀectively blocking the CD95 (APO-1) and p53 expression, and PARP cleavage in
Cin-treated cells. This study indicates that Cin was the most potent antiproliferative constituent of C. cassia, and its apoptotic
mechanism in Hep G2 cells could be mediated through the p53 induction and CD95 (APO-1) signaling pathways.
1.Introduction
Cinnamomum cassia Presl. (Lauraceae) has been tradi-
tionally used to treat dyspepsia, gastritis, blood circula-
tion disturbances and inﬂammatory diseases [1]; it is an
important ingredient in herbal preparations [2, 3]. Its
major components cinnamaldehyde (Cin), cinnamic acid
(Ca) and cinnamyl alcohol (Cal) were reported to have
various biological activities. For example, Ca possessed
antioxidant, anti-inﬂammatory and anticancer properties
[4–6]. Cal is a fragrance ingredient, which is used in
cosmetics, shampoos, soaps and other toiletries [7]. Cin
exhibited antifungal, antipyretic, antioxidant, antimicrobial
and larvicidal activities [8–10], as well as modulating T-
cell diﬀerentiation [11]. In anticancer study, Cin was active
against human liver, lung and leukemia cancer cells [12–14].
However, the antihepatoma activity and mechanism(s) of
action of Cin, Ca and Cal in Hep G2 cells have never been
investigated.
In our previous studies, p53 induction and MAPK
pathways were shown to require for Cin-mediated apoptosis
in PLC/PRF/5 cells [14]. In this study, we examined the
anti-hepatoma activity of C. cassia bioactive components in
Hep G2 cell lines. Hep G2 cells are highly diﬀerentiated
cells [15], whereas PLC/PRF/5 is less divided but highly
migrated hepatoma cells [16]. It functionally behaves as
highly diﬀerentiated liver parenchymal cells and is karyolog-
ically distinguishable from PLC/PRF/5 due to the presence of
trisomy 6 (pter leads to q14) and a long arm of chromosome
15q+ [15]. Hep G2 not PLC/PRF/5 cells secrete IGF carrier
protein [17]a n dp r o d u c eα-2-plasmin inhibitor (α-PI), a
physiological inhibitor [18]. PLC/PRF/5 cells possess mutant
or null p53 protein whereas Hep G2 cells have wild-type p53
protein [14, 19].2 Evidence-Based Complementary and Alternative Medicine
Apoptosis is a process in which cell death is initiated and
completed in an orderly manner through activation and/or
synthesisofgeneproductsnecessaryforcelldestruction[20].
p53 directly activated the promoter of the CD95 (APO-1)
gene in response to DNA damage by anticancer agents.
The upregulation of the CD95 (APO-1) death receptor
was only observed in cells with wild-type p53, but not
in cells with mutant or null p53 [19]. Activation of p53
(a tumor suppressor protein) is known to result in the
altered transcription of a wide variety of genes involving
in-cell metabolism, cell cycle regulation and apoptosis [21,
22]. Both pro-apoptotic (Bax, Bak, Bid, Noxa, etc.) and
anti-apoptotic (Bcl-2, Bcl-XL, Mcl-1, Bcl-w, etc.) proteins
have been reported to be key regulators of apoptosis [23].
Genes transcriptionally upregulated by p53 are implicated
in promoting apoptosis, which includes the Bcl-2 family
members (e.g., Bax, Bak) and Noxa gene proteins [24–
26]. The p53-dependent apoptotic pathway can lead to the
cellular protein cleavage (e.g., PARP), DNA damage and cell
death.
Piﬁthrin-alpha(PFTα;ap53inhibitor)isabletosuppress
p53-mediated transactivation [27]. It signiﬁcantly decreased
p53 expression on wild type p53 cells, but had no eﬀect on
mutant p53 cells or p53-deﬁcient cells [28]. In this study, our
aims were (i) to evaluate the antiproliferative activity of Cin,
Ca and Cal in human hepatoma Hep G2 (CD95-positive)
cells; (ii) to investigate the role of p53, Bcl-2 family proteins
(Bax and Bcl-XL) and PARP in Cin-mediated apoptosis; and
(iii) to study the eﬀects of PFTα on p53 and Bcl-2 family
proteins, as well as PARP cleavage in Hep G2 cells.
2. Methods
2.1.Chemicals. Cin,CaandCalwithpuritygreaterthan98%
werepurchasedfromMerckChemicalIndustries(Germany).
Piﬁthrin-alpha (PFTα) was purchased from Calibiochem
(San Diego, CA, USA). Dulbecco’s modiﬁed Eagle’s me-
dium (DMEM), dimethyl sulfoxide (DMSO), penicillin,
streptomycin, aprotonin, trypsin-EDTA, sodium 3,3 -[1-
(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-
nitro) benzene sulfonic acid (XTT), 5-ﬂurouracil (5FU) and
anti-β-actin body were purchased from Sigma Chemical
Co. (St. Louis, MO, USA). Fetal bovine serum (FBS) was
obtained from GIBCO BRL (Gaithersburg, MD, USA). The
anti-Bax, anti-Bcl-XL, anti-CD95 (APO-1/CD95), anti-p53,
anti-PARP, anti-rabbit IgG and anti-mouse IgG bodies were
purchased from PharMingen (San Diego, CA, USA).
2.2. Preparation of Cell Culture and Test Solutions. The
human hepatoma Hep G2 cells (ATCC HB-8065) were
obtained from the American Type Culture Collection
(Rockville, MD, USA). They were grown in DMEM sup-
plemented with 10% FBS, 100unitsmL−1 penicillin and
100μgmL −1 streptomycin at 37◦C in a humidiﬁed atmo-
sphere of 5% CO2. All stock solutions were prepared in
DMSO at a concentration of 10mM and stored at –20◦C
until use. The concentrations of test compounds used for
this study were 1, 10, 30, 50 and 70μM, which were
freshly prepared for each experiment with a ﬁnal DMSO
concentration of 0.1%. Control samples were always treated
with the same amount of DMSO (0.1% v/v) as used in the
corresponding experiments.
2.3. Analysis of Antiproliferative Activity. Cells were seeded
at a density of 1×105 cells per well on 12-well plates. They
were then treated with various concentrations of Cin, Ca,
Cal or 0.1% DMSO (control) for 0, 6, 12 and 24h. After
treatments, cells were washed once before adding 100μLo f
FBS-free medium containing XTT, followed by incubating
at 37◦C for 4 h. The absorbance of samples was measured
with an ELISA reader (Bio-Rad, USA) at a test wavelength of
492nm and a reference wavelength of 690 nm.
2.4. Piﬁthrin-alpha (PFTα; A p53 Inhibitor) Treatment. Cells
were assured to grow normally before inhibitor treatment.
Conﬂuent cells in each experiment were pretreated for 1h
with 30μMP F T α dissolving in DMSO. The cells were
treated with 30μM Cin or 0.1% DMSO (control) for 24h
and then harvested for apoptotic assays. The inhibitor was
prepared according to the manufacturer’s instructions. In all
experiments, the vehicle used to prepare stock solutions was
noted to have no eﬀect on the cell viability.
2.5. Analysis of PFTα Eﬀects on Cin-Induced Apoptosis. Cells
were seeded at a density of 1×105 cells per well onto 12-
well plates. They were treated with 0.1% DMSO (control) or
30μMCin onlyorpretreatedwith30μMPFTαfor 1h before
adding 30μM Cin. After 24h of treatment, cells were washed
once before adding 100μL of FBS-free medium containing
XTT. After 4h of incubation at 37◦C, the absorbance of
samples was measured with an ELISA reader.
3. Western Immunoblot Analysis
Cells were harvested and subjected to procedures described
previously [14]. The speciﬁc primary antibodies used in
this study were anti-Bax (1:250), anti-Bcl-XL (1:500), anti-
CD95/APO-1 (1:5000), anti-p53 (1:500) and anti-PARP
(1:500) antibodies.
3.1. Statistical Analysis. Values were evaluated by one-way
ANOVA, followed by Duncan’s multiple range tests using the
Statistical Analysis System (SAS Institute, Cary, NC, USA).
DiﬀerenceswereconsideredsigniﬁcantwhentheP-valuewas
< .05.
4. Results
4.1. Antiproliferative Activity of Cin, Ca and Cal in Hep
G2 Cells. To examine the antiproliferative eﬀect of Cin, Ca
and Cal on Hep G2 cells, cells were treated with diﬀerent
concentrations of these compounds using XTT assay. Results
showed that all test compounds exhibited inhibitory eﬀects
on the growth of Hep G2 cells, with an IC50 value of 9.76 ±
0.67μMforCin,34.20 ±0.99μMforCaand58.30 ±1.49μM
for Cal (Figure 1). The potency of Cin was closed to that ofEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: IC50 values of antiproliferative activity of cinnamalde-
hyde, cinnamic acid and cinnamyl alcohol. The data shown are
means ± SD of three independent experiments. Bars with diﬀerent
alphabetical letters were signiﬁcantly diﬀerent at P < .05.
thepositivecontrol5FU(IC50 9.57 ±0.61μM).Hence,itwas
selected for detailed study of apoptotic mechanism.
4.2. Inhibition of Cell Proliferation by Cin. As shown in
Table 1, Cin inhibited the proliferation of Hep G2 cells in
a dose- and time-dependent manner. Compared with the
control, Cin at 30μM caused a nearly 71% inhibition of
cell growth as demonstrated by a signiﬁcant increase in the
number of apoptotic cells. This concentration of Cin was
used in all further experiments.
4.3. CD95 (APO-1/CD95) Is Involved in Cin-Induced Apop-
tosis. CD95 (APO-1/CD95) pathway has been well docu-
mented to participate in certain anticancer drugs-induced
apoptosis. In this study, results showed that Cin caused
a time-dependent increase in the CD95 (APO-1/CD95)
protein expression in Hep G2 cells (Figure 2).
4.4. Cin Treatment Downregulates Bcl-XLand Upregulates Bax
and p53 Protein Levels. Treatment with 30 μMC i nr e s u l t e d
in the downregulation of the anti-apoptotic (Bcl-XL)a n d
the upregulation of the pro-apoptotic (Bax) proteins in a
time-dependent fashion (Figure 2). The expression of Bcl-XL
protein was noted to disappear after 24h of Cin treatment.
As expected, Cin did cause an increase in the level of p53 as
Hep G2 cells contain wild-type p53.
4.5. Cin-Induced Apoptosis Exhibits PARP Cleavage. To fur-
ther conﬁrm the Cin-induced apoptosis, cells were treated
withCinfor0,6,12and24h.PARPcleavagewasdetermined
by immunoblotting analysis. Results showed that PARP
proform (molecular mass, 116kDa) was cleaved to give an
8 5 k D af r a g m e n ti nC i n - t r e a t e dc e l l sa t1 2a n d2 4 ha f t e r
treatment (Figure 2).
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Figure 2: Eﬀects of apoptotic signal transduction factors (CD95,
p53, Bax, Bcl-XL and PARP) in Cin-induced cell death. Cells were
treated with 30μM Cin for 0, 6, 12 and 24h and then harvested for
Western blotting analysis. β-Actin was used as a positive control.
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Figure 3: Eﬀects of the p53 inhibitor (PFTα) on Cin-induced cell
death. The data represent means ± SD of three independent exper-
iments. Bars with diﬀerent alphabetical letters were signiﬁcantly
diﬀerent at P < .05.
4.6. Piﬁthrin α (PFTα) Prevents the Cin-Induced Apoptosis.
To determine whether the Cin induction of apoptosis was
aﬀected by the presence of 30μMP F T α,H e pG 2c e l l s
were pre-incubated with PFTα for 1h, and then induced to
undergo apoptosis by treatment with Cin. Results showed
that PFTα signiﬁcantly (P < .05) inhibited the Cin-induced
Hep G2 cell death (Figure 3).
4.7. PFTα Suppresses the Expression of CD95 (APO-1/CD95),
p53 and Bax Proteins. To evaluate the relative role of CD95
(APO-1/CD95), p53, Bcl-2 family (Bax, Bcl-XL) proteins
and PARP cleavage in the Cin-induced apoptotic events,
c e l l sw e r ep r e t r e a t e dw i t hP F T α. Results displayed that
pre-incubation the Hep G2 cells with 30μMP F T α alone
and 30μMP F T α +3 0 μMC i ne ﬀectively inhibited the
expression of Bax, p53 and CD95, as well as the cleavage
of PARP (Figure 4). These pretreatment also prevented the
downregulation of Bcl-XL in cells.4 Evidence-Based Complementary and Alternative Medicine
Table 1: Eﬀects of Cin-induced apoptosis on human Hep G2 cells.
Cin treatment (μM) Apoptotic cells (%)
0h 6h 12h 24h
00 . 1 0 ± 0.00c 0.10 ± 0.08d 0.10 ± 0.08d 0.13 ± 0.05d
10 . 5 0 ± 0.16c 8.25 ± 0.94c 17.07 ± 0.74c 41.13 ± 0.74c
10 5.00 ± 0.82b 13.20 ± 0.80b 45.96 ± 0.23b 50.10 ± 0.70b
30 16.98 ± 0.14a 38.67 ± 2.49a 60.32 ± 0.50a 70.73 ± 3.03a
Aftertreatment,cellnumberswereestimatedbytheXTTassay.Dataarepresentedasmeans ±SDofthreeindependentexperiments.Valueswithinthecolumn
with diﬀerent superscript letters were signiﬁcant at P < .05.
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Figure 4: Eﬀects of p53 inhibitor (PFTα) on Cin-induced apopto-
sis. Hep G2 cells were treated without or with 30μMP F T α for 1h,
and then in the presence or absence of 30μM Cin for 24h. The total
cell lysate was then analyzed by western blotting analysis. β-Actin
w a su s e da sap o s i t i v ec o n t r o l .
5. Discussion
We have demonstrated that the major components of C. cas-
sia, that is, Cin, Ca and Cal possessed a diﬀerent magnitude
of antiproliferative eﬀect on human hepatoma Hep G2 cells.
Among them, Cin was the most potent compound, which
exhibited an IC50 value closed to that of the commercial
anticancer agent 5FU.
Cin has been shown to possess antitumor activity
through inhibiting cell proliferation and inducing cell apop-
tosis [29–31]. Its inhibitory eﬀect on cell cycle progression
was demonstrated to be through the arrest of the S phase
in human PLC/PRF/5 cells [31]. In this study, the eﬀect
of Cin on Hep G2 cell apoptosis was noted to be on the
CD95(APO-1/CD95)signaltransductionandp53pathways.
It was also found that pretreatment with a p53 inhibitor
(PFTα) could block the process of programmed cell death
and prevent the apoptotic signal transduction pathway.
Several studies have shown that the Bcl-2 family of
proteins is the central of apoptotic regulation [32, 33].
Overexpression of Bcl-2 and Bcl-XL aborts the apoptotic
response while Bax, Bid and Bak activity promotes cell death
[32]. Our results displayed that Cin activated wild-type p53
and caused an up-expression of Bax as well as triggering the
down-expression of Bcl-XL with a subsequent promotion of
CD95
PFTα PFTα
PFTα
PFTα
PFTα
DNA damage
↑p53
↑Bax
PARP cleavage
Cin
Apoptosis
Bcl-XL
Figure 5 :T h em o d eo fa c t i o no fP F T α on the Cin-mediated
apoptosis in Hep G2 cells.
the apoptotic activity in Hep G2 cells. p53 has been reported
to mediate Bax upregulation [25]. It is possible that the Cin-
mediated activation of Bax triggers the cleavage of PARP and
lead to a p53-dependent pathway. The apoptotic induction
in wild-type p53 cells has also been noted on taiwanin A and
gambogic acid [34, 35].
PFTα, a small molecule identiﬁed as an inhibitor of p53
transcriptional activity, has been shown to protect against
the toxic side eﬀects of anticancer treatment to the normal
tissues [36, 37]. It may also interfere with the apoptosis of
tumor cells that sense DNA damage in response to genotoxic
stress [38]. In this study, PFTα was able to completely inhibit
the modulation of CD95 (APO-1/CD95), p53 and Bax
proteins, and the suppression of the PARP cleavage in Cin-
treated cells. This indicates that PFTα signiﬁcantly prevented
Cin-mediated apoptosis through blocking the expression of
apoptotic signal factors such as CD95 (APO-1/CD95), Bax,
p53 and PARP degradation in Hep G2 cells (Figure 5).
6. Conclusion
Among the major components of C. cassia, Cin has demon-
strated to possess the most potent antiproliferative activity in
Hep G2 cells. It was the ﬁrst study to demonstrate the role ofEvidence-Based Complementary and Alternative Medicine 5
CD95 (APO-1/CD95) and p53 in the Cin-induced apoptotic
signaling. In addition, PFTα was found to markedly block
the Cin-induced apoptosis through upregulating the anti-
apoptotic (Bcl-XL) and downregulating the pro-apoptotic
( B a x )p r o t e i n s ,a sw e l la ss u p p r e s s i n gt h eP A R Pc l e a v a g e .
Importantly, PFTα completely attenuated the activation of
CD95 (APO-1/CD95) and p53 in Cin-treated cells. These
results suggest that the modulation of apoptotic pathways
through the CD95 (APO-1/CD95), p53, PARP cleavage and
Bcl-2 family proteins signaling transductions could be an
important therapeutic goal in the prevention and treatment
of cancer.
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